S Science
5721
RVH
6786
Aun Consulting
2459
K Pharma
4896
Intertrade
3747
(Q3)Dec 31, 2024 | (Q1)Jun 30, 2024 | (FY)Mar 31, 2024 | (Q4)Mar 31, 2024 | (Q3)Dec 31, 2023 | (Q2)Sep 30, 2023 | (Q1)Jun 30, 2023 | (FY)Mar 31, 2023 | (Q4)Mar 31, 2023 | (Q3)Dec 31, 2022 | |
---|---|---|---|---|---|---|---|---|---|---|
Total revenue | 10.85%6.31B | 16.50%6.39B | -2.40%22.68B | 3.41%5.68B | -4.72%5.69B | -4.57%5.81B | -3.23%5.49B | 10.25%23.23B | 0.82%5.49B | 11.47%5.98B |
Cost of revenue | 10.72%3.84B | 16.18%3.93B | -3.65%13.94B | 3.48%3.52B | -4.91%3.47B | -7.82%3.57B | -4.62%3.38B | 9.98%14.46B | -1.35%3.4B | 5.48%3.64B |
Gross profit | 11.06%2.48B | 17.01%2.47B | -0.33%8.74B | 3.30%2.16B | -4.43%2.23B | 1.12%2.24B | -0.92%2.11B | 10.69%8.77B | 4.55%2.09B | 22.31%2.33B |
Operating expense | 15.60%1.49B | 9.62%1.4B | 1.52%5.17B | 0.30%1.3B | 1.04%1.29B | 2.19%1.3B | 2.60%1.28B | 8.91%5.09B | 2.88%1.3B | 4.43%1.27B |
Staff costs | 10.64%694.08M | 12.20%679.97M | -1.65%2.46B | -4.47%614.58M | 6.73%627.31M | -3.43%609.68M | -4.78%606.05M | 1.06%2.5B | -1.40%643.32M | -8.89%587.75M |
Research and development costs | 11.00%249.68M | 5.80%236.97M | 9.93%952.81M | 22.08%258.62M | -10.48%224.94M | 22.91%245.27M | 9.76%223.99M | 28.34%866.74M | -3.04%211.84M | 32.98%251.27M |
Other operating expenses | 25.15%543.33M | 8.04%486.99M | 1.89%1.76B | -3.18%429.19M | 0.01%434.15M | 0.84%442.8M | 10.54%450.74M | 13.05%1.72B | 13.33%443.27M | 12.71%434.12M |
Operating profit | 4.86%988.32M | 28.44%1.06B | -2.90%3.57B | 8.20%859.24M | -11.00%942.49M | -0.32%941.22M | -5.92%828.61M | 13.25%3.68B | 7.40%794.11M | 54.01%1.06B |
Net non-operating interest income (expenses) | -357.84%-11.55M | 80.66%-684K | 107.05%2.4M | 144.72%2.37M | 161.49%4.48M | 89.69%-910K | 72.10%-3.54M | 10.38%-34.08M | 56.71%-5.3M | 42.37%-7.28M |
Non-operating interest income | -61.62%6.63M | 112.02%17.12M | 198.58%51.62M | 138.67%15.46M | 238.51%17.27M | 161.42%10.81M | 413.41%8.08M | -1.32%17.29M | 136.68%6.48M | 262.62%5.1M |
Non-operating interest expense | 42.07%18.18M | 53.35%17.81M | -4.19%49.21M | 11.18%13.09M | 3.29%12.79M | -9.58%11.72M | -18.51%11.61M | -7.52%51.37M | -21.36%11.78M | -11.82%12.39M |
Net investment income | 267.47%217.35M | -59.83%103.84M | -31.81%287.16M | 660.10%118.43M | 34.64%-129.79M | -83.81%40M | -27.61%258.51M | 91.31%421.14M | -89.87%15.58M | -508.16%-198.58M |
Gain(Loss) on financial instruments designated as cash flow hedges | ||||||||||
Gain(Loss) on derecognition of available-for-sale financial assets | ||||||||||
Income from associates and other participating interests | ||||||||||
Special income (charges) | -179.73%-37.03M | 93.71%-30M | -873.16%-615.91M | -17,285.11%-138.91M | -782.27%-13.24M | 294.63%13.24M | -734.60%-477M | 79.66M | -799K | 1.94M |
Less:Other special charges | 179.73%37.03M | -93.71%30M | 716.77%491.32M | 1,692.49%14.32M | 782.27%13.24M | -294.63%-13.24M | 734.60%477M | ---79.66M | --799K | ---1.94M |
Less:Write off | ---- | ---- | --124.59M | ---- | ---- | ---- | ---- | --0 | ---- | ---- |
Other non-operating income (expenses) | 42.13%41.18M | 73.40%26.91M | -76.37%32.23M | -132.51%-10.73M | -32.19%28.97M | -103.91%-1.52M | -28.69%15.52M | 172.37%136.41M | 218.42%33.02M | 246.53%42.72M |
Income before tax | 43.86%1.2B | 87.16%1.16B | -23.45%3.28B | -0.74%830.4M | -7.22%832.92M | -19.00%992.02M | -52.95%622.1M | 23.03%4.28B | -6.14%836.61M | 21.99%897.75M |
Income tax | 133.19%460.58M | 11.17%361.58M | 0.45%1.13B | 46.09%358.06M | -18.06%197.51M | -11.95%248.33M | -8.62%325.25M | 43.97%1.12B | 77.54%245.1M | 6.29%241.03M |
Net income | 16.10%737.69M | 170.41%802.73M | -31.95%2.15B | -20.15%472.34M | -3.25%635.41M | -21.11%743.69M | -69.27%296.85M | 16.97%3.16B | -21.47%591.52M | 28.97%656.72M |
Net income continuous operations | 16.10%737.69M | 170.41%802.73M | -31.95%2.15B | -20.15%472.34M | -3.25%635.41M | -21.11%743.69M | -69.27%296.85M | 16.97%3.16B | -21.47%591.52M | 28.97%656.72M |
Noncontrolling interests | ||||||||||
Net income attributable to the company | 16.10%737.69M | 170.41%802.73M | -31.95%2.15B | -20.15%472.34M | -3.25%635.41M | -21.11%743.69M | -69.27%296.85M | 16.97%3.16B | -21.47%591.52M | 28.97%656.72M |
Preferred stock dividends | ||||||||||
Other under preferred stock dividend | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Net income attributable to common stockholders | 16.10%737.69M | 170.41%802.73M | -31.95%2.15B | -20.15%472.34M | -3.25%635.41M | -21.11%743.69M | -69.27%296.85M | 16.97%3.16B | -21.47%591.52M | 28.97%656.72M |
Gross dividend payment | ||||||||||
Basic earnings per share | 18.80%67.62 | 183.45%74.01 | -30.88%191.94 | -16.39%43.5 | -1.45%56.92 | -21.12%65.41 | -69.27%26.11 | 16.97%277.68 | -21.46%52.03 | 28.97%57.76 |
Diluted earnings per share | 18.80%67.62 | 183.45%74.01 | -30.88%191.94 | -16.68%43.348 | -1.45%56.92 | -21.12%65.4051 | -69.27%26.11 | 16.97%277.68 | -21.46%52.0266 | 28.99%57.76 |
Dividend per share | 0 | 0 | 246.67%26 | 246.67%26 | 0 | 0 | 0 | 0.00%7.5 | 0.00%7.5 | 0 |
Currency Unit | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY |
Accounting Standards | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP |